USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
VASCULOX, INC.
Address:
4320 Forest Park Avenue
Suite 303
SAINT LOUIS, MO
Phone:
N/A
URL:
EIN:
126201281
DUNS:
794768551
Number of Employees:
7
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $479,423.00 2
SBIR Phase II $2,665,514.00 2
STTR Phase I $497,398.00 2

Award List:

Treatment of Transplant Reperfusion with an Anti-CD47 Antibody

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$203,191.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Organ transplantation is one of the great success stories of modern medicine. However, the supply of suitable organs lags far behind the need and many patients die while waitlisted for organs. Current practice involves donor preconditioning to stabilize organs… More

Anti-CD47 mAb Therapy to Improve Kidney Transplantation

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$276,232.00
Agency:
HHS
Principal Investigator:
Pamela A. Toy-manning – 314-223-3799
Abstract:
DESCRIPTION (provided by applicant): Organ transplantation is one of the great success stories of modern medicine. However, the supply of suitable organs lags far behind the need and many patients die while waitlisted for organs. While there have been manyrecent strides in organ procurement,… More

Treatment of Transplant Reperfusion with CD47 antibody

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,533,751.00
Agency:
HHS
Principal Investigator:
Pamela A. Toy-manning – 314-223-1400
Abstract:
DESCRIPTION (provided by applicant): Vasculox, Inc. is developing a humanized anti-CD47 mAb for reducing ischemia-reperfusion injury (IRI) in organ transplantation. In spite of improvements in surgical technique, organ preservation and immunosuppression, IRI remains a serious limitation and is… More

Tumor-toxic CD47 mAb therapy for leukemia: a proof of concept study

Award Year / Program / Phase:
2013 / STTR / Phase I
Award Amount:
$299,687.00
Agency:
HHS
Principal Investigator:
William A. Frazier – 314-362-3348
Research Institution:
WASHINGTON UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): CD47 has emerged as a novel therapeutic target in hematologic cancers. Leukemias expressing the highest levels of CD47 have the worst prognosis. Increased CD47 expression is thought to protect cancer cells from phagocytic clearance by sending a don't eat me… More

Anti-CD47 mAb Therapy to Improve Kidney Transplantation

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$1,131,763.00
Agency:
HHS
Principal Investigator:
Pamela A. Toy-manning – 314-932-4037
Abstract:
DESCRIPTION (provided by applicant): Organ transplantation is a lifesaving option for those with end stage renal disease. In spite of many improvements in organ procurement, transplant procedures and immune suppression, the damage done by ischemia-reperfusion injury (IRI) remains problematic,… More